American Century Companies’s Abeona Therapeutics ABEO Stock Holding History

American Century Companies’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57K	Buy	+12,718	New	+$63.6K	﹤0.01%	2807

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies's ABEO Position: Q1 2026 in Review

American Century Companies opened a new position in Abeona Therapeutics (ABEO) in Q1 2026: 12,718 shares worth $57K. The stake represents ﹤0.01% of the portfolio and ranks #2807 among its holdings.

108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

American Century Companies held 12,718 shares of Abeona Therapeutics worth $57K as of Q1 2026.
Abeona Therapeutics was a new American Century Companies position in Q1 2026.
Abeona Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q1 2026, its #2807 holding.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.